Headquartered in Palo Alto, CA Fiscal year ends December NASDAQ: BBIO bridgebio.com
BridgeBio Pharma is a commercial-stage, multi-product biopharmaceutical company that develops medicines for genetic conditions.
Its marketed product is Attruby (acoramidis), a near-complete (≥90%) transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby is approved in the U.S., EU, Japan, Switzerland, Brazil, the U.K., and Australia. Bayer markets it as BEYONTTRA in the EU and Japan, and BridgeBio earns royalties and milestone payments under that license.
The company uses a decentralized hub-and-spoke model: condition-focused teams draw on centralized clinical, regulatory, and commercial capabilities. Late-stage candidates include:
- **BBP-418**, a glycosylation substrate for limb-girdle muscular dystrophy type 2I/R9 (PDUFA November 27, 2026).
- **Oral infigratinib**, an FGFR3 inhibitor for achondroplasia (PDUFA February 4, 2027) and hypochondroplasia.
- **Encaleret**, a calcium-sensing receptor antagonist for ADH1 (PDUFA May 8, 2027) and chronic hypoparathyroidism (Phase 3 RECLAIM-HP).
- **BBP-717**, an amyloid-depleting monoclonal antibody for ATTR-CM, with an IND planned in 2027. Updated
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was “Welcome back, my friends to the show that never ends.” On cue, the never-say-die…
BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with…
Pre-Market Stock Futures: Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle’s disappointing earnings after the bell yesterday. The Federal Reserve’s 25-basis-point rate cut, as expected,…
The latest Consumer Price Index (CPI) report has sparked optimism, revealing consumer prices rose 0.2% in July, meaning the index held steady from June at 2.7%. This was milder than anticipated, but…
A Fallen Giant Pfizer (NYSE:PFE | PFE Price Prediction) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted…
Wednesday's top analyst upgrades and downgrades included Accenture, Bridgebio Pharma, Chesapeake Energy, eBay, Hewlett Packard Enterprise, Huntsman, New York Community Bancorp, Nucor, Oracle, PBF Energy, Phillips 66, United States Steel and Valero…
Wednesday’s top analyst upgrades and downgrades included Adobe, Akamai Technologies, BridgeBio Pharma, Ciena, Eqonex, Hilton Worldwide, Paysafe, Riot Blockchain, Shopify, Tesla and Williams-Sonoma.
BridgeBio Pharma is a commercial-stage, multi-product biopharmaceutical company that develops medicines for genetic conditions. Its marketed product is Attruby (acoramidis), a near-complete (≥90%) transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM).
24/7 Wall St.'s 12-month price target for BBIO is $123.55, rated Buy. The Wall Street consensus target is $107.25. BBIO price prediction →
